Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Hodgkin Disease 3Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Uveal Melanoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pediatric Brain Tumor 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma 1Glioblastoma 1Burkitt Lymphoma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 54Nivolumab 51Ipilimumab 29Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Interleukin-2 8Biopsy 8aldesleukin 7Blood Specimen Collection 7atezolizumab 6Immunotherapy 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3fludarabine phosphate 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Carmustine × Clear all
NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

Thomas Jefferson University

Phase 1/2 Recruiting
109 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡